Special Issues
Table of Content

Autoantibodies and Emerging Biomarkers in Immune-Mediated Neurological Disorders

Submission Deadline: 15 May 2026 View: 683 Submit to Special Issue

Guest Editors

Dr. Tsvetelina Velikova

Email: tsvelikova@medfac.mu-sofia.bg

Affiliation: Medical Faculty, Sofia University St. Kliment Ohridski, Sofia 1407, Bulgaria

Homepage: www.drvelikova.com

Research Interests: autoimmunity, autoimmune diseases, inflammation, neuroinflammation, biomarkers, cytokines

图片2.png


Dr. Georgi Vasilev

Email: vvasilev.georgi@gmail.com

Affiliation:  Multiprofile Hospital for Active Treatment  "Uni Hospital", Panagyurishte 4500, Bulgaria

Medical Faculty, Sofia University St. Kliment Ohridski, Sofia 1407, Bulgaria

Department of Neurology, University Multiprofile Hospital for Active Treatment in Neurology and Psychiatry "St. Naum", Medical University of Sofia, Sofia 1113 , Bulgaria

Research Interests: neuroimmunology, neuroendocrinology, cerebrovascular disease, critical care, internal medicine

wechat_2025-08-06_161448_344.png



Summary

Autoantibodies and emerging biomarkers have become essential focal points in understanding immune-mediated neurological disorders. These complex diseases involve intricate interactions between the immune system and the nervous system, where autoantibodies contribute to neuronal damage and disease progression. Recent studies emphasize the critical role of cellular and molecular mechanisms in the generation of autoantibodies, their pathogenic effects, and the identification of novel biomarkers that aid in diagnosis, prognosis, and therapeutic monitoring.

This Special Issue aims to highlight the latest advances in dissecting the cellular and molecular pathways underlying autoantibody production and function, as well as the discovery and validation of emerging biomarkers in immune-mediated neurological diseases. By focusing on these processes at the cellular level, we seek to deepen mechanistic understanding and promote innovative diagnostic and therapeutic strategies.

Subtopics of interest include, but are not limited to:
1. Cellular mechanisms of autoantibody generation and regulation
Investigations into the immune cell types and signaling pathways responsible for the production and modulation of pathogenic autoantibodies.
2. Pathogenic roles of autoantibodies in neuronal injury and signaling disruption
Studies exploring how autoantibodies affect neuronal cells and synaptic function through molecular and cellular interactions.
3. Emerging biomarkers: discovery, cellular sources, and functional roles
Research focusing on novel biomarkers derived from immune and neural cells that can improve disease diagnosis and monitoring.
4. Neuroimmune communication and microenvironment in disease progression
Insights into how immune cells interact with neural cells and the local environment to influence inflammation and neurodegeneration.
5. Cellular mechanisms underlying immunomodulatory therapies and biomarker-guided treatment
6. Evaluation of how immune-targeted therapies affect cellular processes and biomarker dynamics in patients.

This Special Issue welcomes interdisciplinary contributions integrating immunology, neurobiology, cell biology, and clinical research. We encourage original research articles, comprehensive reviews, and short communications that advance our understanding of autoantibodies and biomarkers in immune-mediated neurological disorders and foster translational applications for improved patient care.


Graphic Abstract

Autoantibodies and Emerging Biomarkers in Immune-Mediated Neurological Disorders

Keywords

autoantibodies, emerging biomarkers, immune-mediated neurological disorders, cellular mechanisms, neuroimmune interactions, neuronal injury, immunomodulatory therapy, biomarker discovery, neuroinflammation.

Published Papers


  • Open Access

    ARTICLE

    sIL-2RA Exacerbates Multiple Sclerosis by Activating Microglia and Upregulating Fc Receptors on Microglia

    Jingfei Shi, Yi Ding, Hui Lu
    BIOCELL, Vol.50, No.3, 2026, DOI:10.32604/biocell.2026.073956
    (This article belongs to the Special Issue: Autoantibodies and Emerging Biomarkers in Immune-Mediated Neurological Disorders)
    Abstract Objective: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). Soluble interleukin-2 receptor alpha (sIL-2Rα) has been implicated in MS pathogenesis, but its mechanisms remain unclear. This study investigates how sIL-2Rα exacerbates MS by modulating microglial activation and antibody-dependent cellular cytotoxicity (ADCC) in an experimental autoimmune encephalomyelitis (EAE) mouse model. Methods: Female C57BL/6J mice were induced with EAE and treated with sIL-2Rα. Clinical symptoms, histopathology, and molecular changes were analyzed. Microglial activation was assessed via immunohistochemistry, Western blot, and RNA sequencing. In vitro, ADCC-mediated oligodendrocyte injury was evaluated using More >

Share Link